Top Atorvastatin Brands to Consider for Quality and Value

Atorvastatin, a widely used medication for managing cholesterol levels, is produced by several reputable pharmaceutical brands known for their quality and effectiveness. Brands like Pfizer, known for inventing Lipitor, often top the list due to their extensive research and development backing. Other notable manufacturers include Teva Pharmaceuticals and Sandoz, which offer generic versions that provide more affordable options without compromising quality. To explore a more comprehensive list of the best atorvastatin brands and their unique offerings, we invite you to read on below.

Illustration of atorvastatin

Best brands of atorvastatin in 2025

Pfizer

Pfizer's Lipitor, a leading statin for reducing cholesterol, continues to generate significant revenue even after its patent expiration in 2011, with annual sales of approximately $2 billion, largely driven by the vast Chinese market. Despite fierce competition from generic atorvastatin, Lipitor maintains a strong presence globally, with a substantial market share, particularly in emerging markets. In 2006, Lipitor sales peaked at nearly $13 billion, and while U.S. sales have dwindled, the brand remains lucrative internationally. Pfizer's strategic pricing adjustments have been crucial in sustaining Lipitor's sales. The global atorvastatin market, including Lipitor, is projected to grow at a CAGR of 3.8% from 2024 to 2031. For further details, you can visit this insightful article on Pfizer's Lipitor.

Teva Pharmaceuticals

Teva Pharmaceuticals is a leading producer of atorvastatin, renowned for its high-quality and therapeutically equivalent generic formulations. The global atorvastatin market, which includes Teva's products, is expected to grow at a CAGR of 3.80% from 2024 to 2031, reaching a market size of USD 6003.69 million by 2031. In 2024, the global atorvastatin market size was estimated at USD 4624.2 million, with North America holding over 40% of the global revenue. Teva's commitment to accessibility and affordability has made their atorvastatin products a preferred choice, especially given the significant cost savings associated with generic drugs. The company's focus on research and development ensures innovative formulations that meet stringent regulatory standards.

Apotex Corp.

Apotex Corp., as Canada's largest drug manufacturer, is a leading producer of generic atorvastatin, with over 300 products sold in more than 115 countries. By 2023, Apotex employed close to 8,000 people and had annual sales exceeding CA$2.5 billion. The company is known for its extensive range of generic medications, including those for high cholesterol, and is a member of several pharmaceutical associations. Despite past regulatory issues, Apotex remains a significant player in the global pharmaceutical market. Its commitment to producing high-quality generic drugs has made it a trusted name in the industry.

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is a prominent producer of atorvastatin, the generic version of Lipitor, with a significant presence in the global market. In 2012, the company was set to launch its version of atorvastatin in the US after Ranbaxy's 180-day marketing exclusivity ended, although it faced challenges due to intense price erosion, with prices dropping by as much as 96%. Despite this, Dr. Reddy's has continued to expand its portfolio, filing numerous generic drug applications, including those for complex formulations to mitigate pricing pressures. The global atorvastatin market, in which Dr. Reddy's participates, is projected to grow at a CAGR of 3.8% from 2024 to 2031, reaching $6,003.69 million by 2031. Dr. Reddy's commitment to quality and innovation positions it as a key player in the atorvastatin market. You can find more information about their products on their official website.

Sandoz

Sandoz, a division of Novartis, is a prominent producer of atorvastatin, contributing significantly to the global market. In 2024, the global atorvastatin market size was estimated at USD 4624.2 million, with North America holding over 40% of the market share, a region where Sandoz has a strong presence. Atorvastatin, a statin medication, is highly effective in reducing cholesterol levels and the risk of cardiovascular diseases, with a projected CAGR of 3.80% from 2024 to 2031. Sandoz's generic version of atorvastatin is widely used, especially in regions like Europe and Asia Pacific, where the market is expected to grow at a CAGR of 2.3% and 5.8%, respectively, during the same period. The company's commitment to quality and affordability has made it a trusted name in the pharmaceutical industry. For more information about their atorvastatin products, visit their Sandoz Atorvastatin page.

Aurobindo Pharma

Aurobindo Pharma is a leading producer of atorvastatin, recognized for its high-quality and affordable generic pharmaceuticals. The company has a significant presence in the global market, with 48% of its revenue in 2024 coming from U.S. drug formulations and a notable share from European Union formulations. Aurobindo Pharma has been expanding its portfolio since its first US ANDA approval in 2004 and has become one of the top 10 pharmaceutical companies in terms of total prescriptions dispensed by 2013. The company's atorvastatin products, such as Atorvastatine Aurobindo, have been approved and proven bioequivalent to the reference product, Lipitor. Aurobindo's commitment to quality, affordability, and customer satisfaction has positioned it for consistent growth. For more details about their products, visit their official website.

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries, through its subsidiary Ranbaxy Laboratories Ltd., is a leading producer of atorvastatin, significantly contributing to the global market. The atorvastatin market, which is expected to grow at a CAGR of 10.6% from 2023 to 2028, is driven by increasing demand for cardiovascular treatments and the availability of generic formulations. Sun Pharmaceutical's strong presence in this market is bolstered by its extensive distribution network and competitive pricing. The global atorvastatin market is projected to reach $17.73 billion by 2028, with North America being the largest region in 2023 and Asia-Pacific expected to be the fastest-growing region. Sun Pharmaceutical's commitment to research and development, including innovative formulations and green chemistry, further solidifies its position as a top producer. For more details about their product range, visit Sun Pharmaceutical's website.

Cipla

Cipla is a leading producer of atorvastatin, with a significant market presence in the statin segment. In the Indian market, Cipla, along with other key players like Biocon and Zydus Cadila, has been strategizing to increase its production of statins, driven by the high-value and growing demand for these cholesterol-lowering drugs. Cipla's market share has been on the rise, reporting a 15.5% market share as per IQVIA prescription data for April 2024. The company’s growth is backed by its strong performance in key therapies such as Respiratory, CNS, and Anti-Infectives. Cipla's revenue in North America also saw an 11% year-over-year growth, supported by its differentiated assets and base portfolio. For more information, visit their official site.

Mylan

Mylan, now a part of Viatris, is a prominent producer of atorvastatin, contributing significantly to the global market. In 2024, the global atorvastatin market is expected to reach USD 4624.2 million, with Mylan and Greenstone, under Viatris, playing a crucial role in this sector. According to Medicaid data, Viatris will be responsible for nearly 4% of all prescription volume, including atorvastatin prescriptions. Mylan's atorvastatin, known as MYLAN-ATORVASTATIN, is indicated for adults as an adjunct to lifestyle changes, including diet, and is available in dosages ranging from 10 to 80 mg once daily. The merger between Mylan and Upjohn has consolidated their market presence, although it has raised some competition concerns, particularly for combined products like Amlodipine/Atorvastatin. For more detailed information, you can view the atorvastatin product monograph.

Lupin Pharmaceuticals

Lupin Pharmaceuticals is a leading producer of atorvastatin, having received FDA approval for its Atorvastatin Calcium Tablets USP, which are generic versions of Pfizer's Lipitor. These tablets are available in 10 mg, 20 mg, 40 mg, and 80 mg strengths and are indicated to lower cholesterol and reduce the risk of heart attack and stroke. Lupin's atorvastatin products had annual sales of approximately USD 696 million in the US as of December 2018. The company is the 3rd largest pharmaceutical player in the US by prescriptions and holds a significant global leadership position in the anti-TB segment. Lupin's innovative approach and wide range of formulations make it a prominent player in the pharmaceutical industry.